Literature DB >> 25014218

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells.

Armin Mooranian1, Rebecca Negrulj1, Frank Arfuso2, Hani Al-Salami1.   

Abstract

INTRODUCTION: In a recent study, we confirmed good chemical and physical compatibility of microencapsulated pancreatic β-cells using a novel formulation of low viscosity sodium alginate (LVSA), Poly-L-Ornithine (PLO), and the tertiary bile acid, ursodeoxycholic acid (UDCA). This study aimed to investigate the effect of UDCA on the morphology, swelling, stability, and size of these new microcapsules. It also aimed to evaluate cell viability in the microcapsules following UDCA addition.
MATERIALS AND METHODS: Microencapsulation was carried out using a Büchi-based system. Two (LVSA-PLO, control and LVSA-PLO-UDCA, test) pancreatic β-cells microcapsules were prepared at a constant ratio of 10:1:3, respectively. The microcapsules' morphology, cell viability, swelling characteristics, stability, mechanical strength, Zeta potential, and size analysis were examined. The cell contents in each microcapsule and the microencapsulation efficiency were also examined.
RESULTS: The addition of UDCA did not affect the microcapsules' morphology, stability, size, or the microencapsulation efficiency. However, UDCA enhanced cell viability in the microcapsules 24 h after microencapsulation (p < 0.01), reduced swelling (p < 0.05), reduced Zeta potential (- 73 ± 2 to - 54 ± 2 mV, p < 0.01), and increased mechanical strength of the microcapsules (p < 0.05) at the end of the 24-h experimental period. DISCUSSION AND
CONCLUSION: UDCA increased β-cell viability in the microcapsules without affecting the microcapsules' size, morphology, or stability. It also increased the microcapsules' resistance to swelling and optimized their mechanical strength. Our findings suggest potential benefits of the bile acid UDCA in β-cell microencapsulation.

Entities:  

Keywords:  artificial cell microencapsulation; bile acids; cell viability; diabetes; islet cells

Mesh:

Substances:

Year:  2014        PMID: 25014218     DOI: 10.3109/21691401.2014.934457

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  15 in total

1.  In vitro platform establishes antigen-specific CD8+ T cell cytotoxicity to encapsulated cells via indirect antigen recognition.

Authors:  Ying Li; Anthony W Frei; Ethan Y Yang; Irayme Labrada-Miravet; Chuqiao Sun; Yanan Rong; Magdalena M Samojlik; Allison L Bayer; Cherie L Stabler
Journal:  Biomaterials       Date:  2020-06-15       Impact factor: 12.479

Review 2.  Current stem cell based therapies in diabetes.

Authors:  Meredith A Lilly; Meghan F Davis; Josh E Fabie; Elizabeth B Terhune; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2016-10-20

3.  Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin.

Authors:  Jung Seok Lee; Patrick Han; Rabib Chaudhury; Shihan Khan; Sean Bickerton; Michael D McHugh; Hyun Bong Park; Alyssa L Siefert; Gerald Rea; José M Carballido; David A Horwitz; Jason Criscione; Karlo Perica; Robert Samstein; Ragy Ragheb; Dongin Kim; Tarek M Fahmy
Journal:  Nat Biomed Eng       Date:  2021-10-06       Impact factor: 25.671

4.  Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis.

Authors:  Armin Mooranian; Ryu Tackechi; Emma Jamieson; Grant Morahan; Hani Al-Salami
Journal:  Pharm Res       Date:  2017-03-13       Impact factor: 4.200

5.  The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.

Authors:  Armin Mooranian; Rebecca Negrulj; Frank Arfuso; Hani Al-Salami
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

6.  The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.

Authors:  Armin Mooranian; Rebecca Negrulj; Hani Al-Salami
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

7.  An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques.

Authors:  Armin Mooranian; Nassim Zamani; Ryu Takechi; Giuseppe Luna; Momir Mikov; Svetlana Goločorbin-Kon; Magdy Elnashar; Frank Arfuso; Hani Al-Salami
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

8.  Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies.

Authors:  Susbin Raj Wagle; Daniel Walker; Bozica Kovacevic; Ahmed Gedawy; Momir Mikov; Svetlana Golocorbin-Kon; Armin Mooranian; Hani Al-Salami
Journal:  Sci Rep       Date:  2020-05-07       Impact factor: 4.379

9.  Influence of Biotechnological Processes, Speed of Formulation Flow and Cellular Concurrent Stream-Integration on Insulin Production from β-cells as a Result of Co-Encapsulation with a Highly Lipophilic Bile Acid.

Authors:  Armin Mooranian; Rebecca Negrulj; Ryu Takechi; Emma Jamieson; Grant Morahan; Hani Al-Salami
Journal:  Cell Mol Bioeng       Date:  2017-10-03       Impact factor: 2.321

10.  The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells.

Authors:  Armin Mooranian; Rebecca Negrulj; Hani Al-Salami
Journal:  Pharm Res       Date:  2016-01-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.